The addition of CD44-targeted functionalized nanocarriers into the field of NSCLC therapy necessitates a detailed evaluation in contrast to existing targeted treatments, highlighting unique characteristics and possible collaborative effects (127), the comparison is also mentioned via the Table 2. This evidence concerns the gene CD44 and non-small cell lung carcinoma.